A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
The optimal management of patients with oligorecurrent prostate cancer (PCa) is unknown. There is growing interest in metastasis-directed therapy (MDT) for this population. The objective was to assess cost-utility from a Belgian healthcare payer’s perspective of MDT and delayed androgen de...
Main Authors: | Elise De Bleser, Ruben Willems, Karel Decaestecker, Lieven Annemans, Aurélie De Bruycker, Valérie Fonteyne, Nicolaas Lumen, Filip Ameye, Ignace Billiet, Steven Joniau, Gert De Meerleer, Piet Ost, Renée Bultijnck |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/1/132 |
Similar Items
-
Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy
by: Hiroki Sato, et al.
Published: (2020-08-01) -
Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
by: Gaëtan Devos, et al.
Published: (2020-08-01) -
A cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer
by: E. De Bleser, et al.
Published: (2020-07-01) -
Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
by: Patrick Berkovic, et al.
Published: (2020-05-01) -
Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis
by: Morino, Koshiro
Published: (2021)